You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 6, 2025

Details for Patent: 7,737,142

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,737,142 protect, and when does it expire?

Patent 7,737,142 protects VRAYLAR and is included in one NDA.

This patent has forty-five patent family members in thirty-four countries.

Summary for Patent: 7,737,142

Title:	(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Abstract:	The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): ##STR00001## wherein R.sub.1 and R.sub.2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R.sub.1 and R.sub.2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
Inventor(s):	Againe Csongor; Eva (Budapest, HU), Galambos; Janos (Budapest, HU), Nogradi; Katalin (Budapest, HU), Vago; Istvan (Budapest, HU), Gyertyan; Istvan (Budapest, HU), Kiss; Bela (Budapest, HU), Laszlovszky; Istvan (Budapest, HU), Laszy; Judit (Nagykovacsi, HU), Saghy; Katalin (Budapest, HU)
Assignee:	Richter Gedeon Vegyeszeti Gyar Rt. (Budapest, HU)
Application Number:	11/337,275
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,737,142
Patent Claim Types: see list of patent claims	Compound; Process; Composition; Use;
Patent landscape, scope, and claims:	United States Patent 7,737,142: A Comprehensive Analysis Introduction United States Patent 7,737,142, titled "(Thio)carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists," is a significant patent in the field of pharmaceuticals, particularly in the development of dopamine receptor ligands. This patent, assigned to Richter Gedeon Vegyeszeti Gyar Rt. (now known as Richter Gedeon Nyrt.), was granted on June 15, 2010. Inventors and Assignees The patent was invented by a team of researchers including Eva Againe Csongor, Janos Galambos, Katalin Nogradi, Istvan Vago, Istvan Gyertyan, Bela Kiss, Istvan Laszlovszky, Judit Laszy, and Katalin Saghy, all from Budapest, Hungary[1][4]. Patent Scope and Claims Chemical Compounds The patent describes new cyclohexane derivatives with (thio)carbamoyl side chains that act as D3 and D2 dopamine receptor antagonists. These compounds are defined by the formula (I), which includes various substituents such as alkyl, phenyl, naphthyl, cyclohexyl, and adamantyl groups. The compounds can also include geometric isomers, stereoisomers, diastereomers, salts, hydrates, and solvates[1][4]. Pharmaceutical Compositions The patent also covers pharmaceutical compositions containing these compounds as active ingredients. These compositions are designed for the treatment of various disorders, including cognitive diseases, mania, anxiety, paranoid schizophrenia, and other conditions related to dopamine receptor dysfunction[1][4]. Patent Claims The patent claims are extensive and include: The specific chemical structures of the (thio)carbamoyl-cyclohexane derivatives. The methods of synthesizing these compounds. Pharmaceutical compositions containing these compounds. Methods of treating various disorders using these compositions[1][4]. Patent Expiration Dates The patent is set to expire on September 17, 2029. This expiration date is crucial as it marks the end of the exclusive rights granted to the patent holder, allowing for the potential development of generic versions of the drug[2]. Related Patents and Formulations Other Relevant Patents Other patents related to this invention include those covering stable and bioavailable immediate release formulations of dopamine receptor ligands. For example, Patent RE47350, issued to Richter Gedeon Nyrt., describes methods for treating various disorders using these formulations and has an expiration date of July 16, 2029[2]. Drug Formulations The patent landscape also includes formulations that enhance the bioavailability and stability of the compounds. These formulations are critical for ensuring the efficacy and safety of the drugs in clinical use[2]. Therapeutic Applications The compounds and pharmaceutical compositions described in the patent are intended for treating a wide range of disorders, including: Cognitive diseases Mania Anxiety Paranoid schizophrenia Parkinsonian diseases Tardive dyskinesia Attention Deficit Disorder with Hyperactivity Autism and autistic disorders Eating and feeding disorders Sexual dysfunction[1][4]. Market Impact and Generic Availability As of the current date, there is no therapeutically equivalent generic version of Vraylar (the drug associated with this patent) available in the United States. The expiration of the patent in 2029 will likely open the market for generic versions, potentially changing the market dynamics and accessibility of these medications[2]. Patent Landscape Overview The patent landscape in the field of dopamine receptor ligands is complex, with multiple patents covering various aspects of drug development, formulation, and therapeutic use. The dominance of patents related to heterocyclic compounds (IPC class C07D) is notable, indicating a significant focus on these chemical structures in pharmaceutical research[3]. Conclusion and Future Implications United States Patent 7,737,142 is a pivotal patent in the development of dopamine receptor antagonists. Its scope and claims cover a broad range of chemical compounds and pharmaceutical compositions, addressing various neurological and psychiatric disorders. As the patent approaches its expiration date, the pharmaceutical industry can anticipate changes in the market, including the potential for generic versions of related drugs. Key Takeaways The patent covers (thio)carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists. It includes pharmaceutical compositions and methods for treating various disorders. The patent expires on September 17, 2029. Related patents cover stable and bioavailable formulations. The therapeutic applications are diverse, including cognitive diseases and psychiatric disorders. No generic version of Vraylar is currently available. FAQs What is the main focus of United States Patent 7,737,142? The main focus of this patent is on (thio)carbamoyl-cyclohexane derivatives that act as D3 and D2 dopamine receptor antagonists. Who are the inventors of this patent? The inventors include Eva Againe Csongor, Janos Galambos, Katalin Nogradi, Istvan Vago, Istvan Gyertyan, Bela Kiss, Istvan Laszlovszky, Judit Laszy, and Katalin Saghy. What disorders are targeted by the compounds described in this patent? The compounds are intended for treating disorders such as cognitive diseases, mania, anxiety, paranoid schizophrenia, Parkinsonian diseases, and others related to dopamine receptor dysfunction. When does the patent expire? The patent is set to expire on September 17, 2029. Is a generic version of Vraylar available? No, as of the current date, there is no therapeutically equivalent generic version of Vraylar available in the United States. Cited Sources: US7737142B2 - (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists - Google Patents Generic Vraylar Availability - Drugs.com Pharmaceutical patent landscaping: A novel approach to ... - bioRxiv US7737142B2 - (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists - Google Patents More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 7,737,142

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE	⤷ Subscribe
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE	⤷ Subscribe
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE	⤷ Subscribe
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE	⤷ Subscribe
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 7,737,142

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Hungary	P0302451	Aug 4, 2003

International Family Members for US Patent 7,737,142

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1663996	⤷ Subscribe	PA2017027	Lithuania	⤷ Subscribe
European Patent Office	1663996	⤷ Subscribe	CR 2017 00042	Denmark	⤷ Subscribe
European Patent Office	1663996	⤷ Subscribe	122017000083	Germany	⤷ Subscribe
European Patent Office	1663996	⤷ Subscribe	300913	Netherlands	⤷ Subscribe
European Patent Office	1663996	⤷ Subscribe	47/2017	Austria	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.